NASDAQ: SONN
Sonnet Biotherapeutics Holdings Inc Stock

$1.43+0.03 (+2.14%)
Updated Apr 30, 2025
SONN Price
$1.43
Fair Value Price
-$0.02
Market Cap
$4.38M
52 Week Low
$1.10
52 Week High
$16.00
P/E
-0.14x
P/B
1.09x
P/S
2.95x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.00M
Earnings
-$9.43M
Gross Margin
100%
Operating Margin
-927.1%
Profit Margin
-942.9%
Debt to Equity
0.78
Operating Cash Flow
-$8M
Beta
0.74
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A

SONN Overview

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine SONN's potential to beat the market

Zen Rating Component Grades

N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
SONN
Ranked
Unranked of 462

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important SONN news, forecast changes, insider trades & much more!

SONN News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SONN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SONN ($1.43) is overvalued by 6,593.29% relative to our estimate of its Fair Value price of -$0.02 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SONN ($1.43) is not significantly undervalued (6,593.29%) relative to our estimate of its Fair Value price of -$0.02 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SONN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SONN due diligence checks available for Premium users.

Valuation

SONN fair value

Fair Value of SONN stock based on Discounted Cash Flow (DCF)

Price
$1.43
Fair Value
-$0.02
Undervalued by
6,593.29%
SONN ($1.43) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SONN ($1.43) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SONN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

SONN price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.14x
Industry
-162.28x
Market
29.18x

SONN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.09x
Industry
4.45x
SONN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SONN's financial health

Profit margin

Revenue
$1.0M
Net Income
-$3.2M
Profit Margin
-316.1%
SONN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
SONN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$7.2M
Liabilities
$3.1M
Debt to equity
0.78
SONN's short-term assets ($6.73M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SONN's short-term assets ($6.73M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SONN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SONN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.9M
Investing
$0.0
Financing
$7.6M
SONN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SONN vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
SONN$4.38M+1.85%-0.14x1.09x
XBIO$4.38M-0.70%-1.11x0.73x
ALZN$4.35M-0.75%-0.22x1.26x
PTN$4.29M-60.90%-0.11x-0.67x
KTTA$4.49M+1.22%-0.13x0.30x

Sonnet Biotherapeutics Holdings Stock FAQ

What is Sonnet Biotherapeutics Holdings's quote symbol?

(NASDAQ: SONN) Sonnet Biotherapeutics Holdings trades on the NASDAQ under the ticker symbol SONN. Sonnet Biotherapeutics Holdings stock quotes can also be displayed as NASDAQ: SONN.

If you're new to stock investing, here's how to buy Sonnet Biotherapeutics Holdings stock.

What is the 52 week high and low for Sonnet Biotherapeutics Holdings (NASDAQ: SONN)?

(NASDAQ: SONN) Sonnet Biotherapeutics Holdings's 52-week high was $16.00, and its 52-week low was $1.10. It is currently -91.06% from its 52-week high and 30% from its 52-week low.

How much is Sonnet Biotherapeutics Holdings stock worth today?

(NASDAQ: SONN) Sonnet Biotherapeutics Holdings currently has 3,065,701 outstanding shares. With Sonnet Biotherapeutics Holdings stock trading at $1.43 per share, the total value of Sonnet Biotherapeutics Holdings stock (market capitalization) is $4.38M.

Sonnet Biotherapeutics Holdings stock was originally listed at a price of $1,001,001.02 in Oct 31, 2006. If you had invested in Sonnet Biotherapeutics Holdings stock at $1,001,001.02, your return over the last 18 years would have been -100%, for an annualized return of -52.66% (not including any dividends or dividend reinvestments).

How much is Sonnet Biotherapeutics Holdings's stock price per share?

(NASDAQ: SONN) Sonnet Biotherapeutics Holdings stock price per share is $1.43 today (as of Apr 30, 2025).

What is Sonnet Biotherapeutics Holdings's Market Cap?

(NASDAQ: SONN) Sonnet Biotherapeutics Holdings's market cap is $4.38M, as of May 1, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Sonnet Biotherapeutics Holdings's market cap is calculated by multiplying SONN's current stock price of $1.43 by SONN's total outstanding shares of 3,065,701.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.